Actively Recruiting
Study of MK-1084 Combined With Other Treatments for Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with KRAS G12C Mutations
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-01
140
Participants Needed
29
Research Sites
138 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether MK-1084, a targeted therapy, can treat advanced or metastatic non-squamous non-small cell lung cancer NSCLC with KRAS G12C mutations. This study aims to evaluate the safety of MK-1084 when taken with other treatments and to see how many participants experience tumor shrinkage or disappearance. The trial is a phase 1b2 umbrella study focusing on previously treated participants with this specific lung cancer type. Participants receive MK-1084 combined with either Patritumab deruxtecan HER3-DXd or Sacituzumab tirumotecan Sac-TMT until treatment is stopped due to side effects, adverse events, or investigator decision. An arm with MK-1084 plus Cetuximab was discontinued. MK-1084 is given orally, and the other drugs are administered by intravenous infusion. Rescue medications for nausea and vomiting may be given as needed. Throughout the study, participants undergo evaluations for dose-limiting toxicities, adverse events, and treatment discontinuations due to side effects, monitored up to approximately 63 months. Researchers also assess tumor response rates and progression-free survival. Biomarker analysis is performed using tumor tissue or circulating tumor DNA. The trial follows participants until the study completion date in 2032, with ongoing safety and effectiveness monitoring.
CONDITIONS
Brief Title
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here